by Cal Strode | Jan 28, 2026
This year marks the fourth consecutive time I’ve covered the Alliance for Regenerative Medicine’s (ARM) State of the Industry briefing for Signals, and I’ve enjoyed tracking how the cell and gene therapy sector has evolved in real time. In 2023 and 2024, the briefings...
by Stacey Johnson | Jan 9, 2026
It’s that time of year when we look back at what was popular on Signals over the past 12 months, according to views. I am always curious to see what you are reading and perhaps you are as well? As we head into our 14th year of publishing Signals, I’m very aware of all...
by Stacey Johnson | Dec 19, 2025
A recent publication on the marketing of stem cell supplements, in the International Society for Stem Cell Research’s (ISSCR) Stem Cell Reports, sparked my curiosity about these products. While I haven’t been able to find a reliable source indicating how long stem...
by Anis Fahandej-Sadi | Jun 5, 2025
Cancer treatment has advanced dramatically, but a central challenge remains: the newest tools in our arsenal are shockingly expensive. CAR T-cell therapies exemplify this—they’re amazing at fighting blood cancers, but a single treatment costs upwards of...
by Kevin Robb | May 22, 2025
For the first time, mesenchymal stromal cells (MSCs) can be used in routine clinical practice under the nod of regulatory approval in the United States. The MSC product known as Ryoncil was made available to patients in March 2025 following a historic decision from...
by Laine Bodnar | Mar 18, 2025
For life science graduates exploring career options, the regulatory affairs function is where scientific expertise meets real-world impact. Regulatory affairs professionals play a crucial role in bringing regenerative medicine – including cell and gene therapies –...
Comments